anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to a process for the production of a separator having hollow fibre membranes, in particular for plasmaphoresis, sterile filtration and enrichment of viruses. The aim and object of the invention are to produce a regenerable and autoclavable separator having microporous hollow fibres, which permits the use of polymers having high chemical and thermal resistance and high filtration performance and in which the penetration of the embedding compounds into the hollow fibres is prevented. 
&lt;??&gt;The non-porous hollow fibres of polyester or polycarbonate are bombarded by charged particles. These hollow fibres are cast to form bundles and are introduced into a separator housing. The latent particle traces in the wall of the hollow fibres are then etched to form pores by a chemical etching using 5 N sodium hydroxide solution, 10% strength acetic acid being pumped into the interior of the hollow fibres. The duration of etching determines the size of the pore diameter. The hollow fibres and the separator housing are then rinsed with distilled water, and the last rinsing process can simultaneously be used for determining characteristic data in quality inspection.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an improved process for preparing modafinil, whereby it may be isolated in high purity by a single operation of crystallization.  &lt;P&gt;SOLUTION: The present process can be used for producing modafinil which is free of sulfone products by over-oxidation and other byproducts. The invention further provides new crystalline forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil forms II-IV and VI.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain a composition for the oral cavity, by blending an extract of Eugenia caryophyllata Thunb. and adjusting the pH within a specific range, capable of sustaining the stability of the extract of the Eugenia caryophyllata Thunb. without causing discoloration and deactivation of inhibitory action on halitosis. CONSTITUTION:A composition for the oral cavity obtained by blending an extract of Eugenia caryophyllata Thunb. known to give deodorizing effect, e.g. inhibition of halitosis, etc., by blending in a dentifrice composition in an amount of 0.0001-2wt%, preferably 0.001-1wt% based on the total composition and adjusting the pH of the composition to 4-7.5, particularly 5.5-7.5. Although the pH is preferably adjusted by using a phosphate based or citric acid based buffer agent, the adjustment can be carried out by blending a polishing agent, e.g. aluminum hydroxide treated with phosphoric acid, having &lt;=8pH of a 10% aqueous suspension thereof.
The invention deals with a method for the determination of the glomerular filtration rate after a single injection of a test dose of a corrinoid and with a method for the determination of tiny amounts of vitamin B12. This may be of importance, for example, in a wide variety of disciplines. An example of this from medicine. Clearance investigations for clinical testing of kidney function are known. Radioactive isotopes are used for this, thus exposing the human body to radioactivity. If it is possible to obtain at least equally good results in clearance investigations without exposing the human body to radioactive isotopes, this would be a great success. This is possible by detection of tiny amounts of vitamin B12 in the human body. This is achieved by saturating the B12 receptors, administering at least one test dose of vitamin B12, and subsequently determining the plasma concentration by HPLC (High Pressure Liquid Chromatography). &lt;IMAGE&gt;
The invention provides application of a nuclear receptor coactivator 4 serving as a target spot in screening and preparing a medicine for treating polycystic ovary syndrome ovulation disorder. The invention also provides application of the reagent for detecting the nuclear receptor coactivator 4 in preparing a kit for diagnosing the ovulation disorder of polycystic ovary syndrome. The invention also provides application of the nuclear receptor coactivator 4 in preparing a marker for diagnosing the ovulation disorder of polycystic ovary syndrome. The invention also provides application of the nuclear receptor coactivator 4 serving as a diagnostic marker in preparing a kit for diagnosing the ovulation disorder of polycystic ovary syndrome. The invention also provides an interfering RNA, the nucleotide sequence of which is 5&#39;-GACCUUAUUUAUCAGCUUATT-3&#39;. The present invention has found that NCOA4 can improve ERK1/2 phosphorylation inhibition by androgens and C/EBP beta expression reduction.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an allergen inactivating agent comprising an edible plant extract as an active ingredient and a skin care preparation or an allergen inactivating product comprising the same compounded therein.  &lt;P&gt;SOLUTION: The allergen inactivating agent comprises one or more kinds of extracts having allergen inactivating effects as an active ingredient selected from the plant group of Agrimonia pilosa var. japonica, Hypericum erectum, Camellia sinensis, Salacia oblonga, Vitis spp, Prunellae spica, Cornus officinalis and Chaenomeles speciosa. The skin care preparation, the cosmetic, the sheet and the interior spray each comprises the extract. The allergen is a pollen allergen and/or a mite allergen.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an oral prophylactic and ameliorating agent for wrinkle formation readily ingestible over a long period and having excellent wrinkle ameliorating effects by oral ingestion.  &lt;P&gt;SOLUTION: This oral prophylactic and ameliorating agent for wrinkle formation comprises an isoflavone glycoside as an active ingredient. In the prophylactic and ameliorating agent, the isoflavone glycoside is especially a 70% ethanol extract from soybeans and the content in the agent is especially 8-15 wt.%. The daily oral intake is especially 8-80 mg. For example, daidzin, genistin or glycitin is cited as the isoflavone glycoside. Furthermore, the agent can be converted into the form of a food.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an evening primrose-derived urease inhibitory composition having high urease inhibitory activity and high in safety as well.  &lt;P&gt;SOLUTION: The urease inhibitory composition comprises a solvent extract of evening primrose. Preferably, this composition comprises a solvent extract of evening primrose seeds, desirably defatted evening primrose seeds. In this composition, the solvent extract is preferably an aqueous ethanol extract desirably 40-90%(wt/wt) in ethanol concentration. This composition is preferably to be used as a material for foods/drinks or medicines.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
NEW MATERIAL:A 4-aminophenol derivative shown by formula I [R&lt;1&gt; and R&lt;2&gt; and lower alkyl, lower alkanoyl, etc.; R&lt;3&gt; is phenyl which is replaced with 1-5 groups selected from lower alkoxy, lower alkanoyloxy, OH, amino, etc., or benzoquinonyl replaced with 1-3C lower alkyl; Y is single bond, lower alkylene, etc.; ZO is (protected) OH] or a pharmaceutically acceptable salt thereof. EXAMPLE:N-(3,4-Diacetoxycinnamoyl)-4-benzyloxy-3,5-dimethylaniline. USE:A drug. An active ingredient of 5-lipoxygenase inhibitor. Useful for treating various kinds of allergies and inflammatory diseases caused by leukotriene and alleviating and preventing symptoms. PREPARATION:An aniline compound shown by formula II or a salt thereof is condensed with a carboxylic acid compound shown by formula III or a reactive derivative or a salt thereof by conventional method of peptide synthesis to give a compound shown by formula I.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new human CC-chemokine receptor, to provide an antibody against the receptor or an antigenic bonded fragment thereof and to provide a pharmaceutical composition comprising the same.  &lt;P&gt;SOLUTION: A mammalian (e.g. human) CCR2 [CC-chemokine receptor (2)] is isolated and the antibody or the functional fragment thereof which binds to the CCR2 or a portion of the receptor and blocks the binding of a ligand to the receptor is isolated. Furthermore, a method for inhibiting an interaction of a cell bearing the mammalian CCR2 with a ligand thereof is provided. The use of the antibody and fragment in prophylactic and diagnostic methods is provided.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide ophthalmic compositions containing three polymers.  &lt;P&gt;SOLUTION: There are provided ophthalmic compositions suitable for use as artificial tears, or ophthalmic compositions suitable for use as vehicles for ophthalmic drugs. The compositions include a combination of three polymers that have a synergistic effect on viscosity. The three polymers are hydroxypropylmethylcellulose, and a combination of two polymers. The combination of the two polymers is selected from the group of combinations consisting of guar gum, and a carboxyvinyl polymer; guar gum, and a hydroxyethylcellulose; guar gum, and dextran; hydroxyethylcellulose, and carboxyvinyl polymer; and dextran, and carboxyvinyl polymer.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
A medical herb composition is disclosed. The herb composition includes: Schizandra chinensis (Turcz.) Baill. material; Panax ginseng C.A.Meyer material; Ophiopogon japonicus KER-GAWLER material; and saliva miltiorrhiza BUNGE material. The herb composition including the materials above is proved that it is efficient in enhancing cardiopulmonary function of a patient without heart disease, enforcing one&#39;s energy and raising one&#39;s strength. The herb composition is also capable for reducing the symptoms of breathing difficulties and depression of liver-energy as well.
Compounds are disclosed for treating AIDS, herpes, and other viral infections by means of lipid derivatives of antiviral agents. The compounds consist of nucleoside analogues having antiviral activity which are linked, commonly through a phosphate group at the 5&#39; position of the pentose residue, to one of a selected group of lipids. The lipophilic nature of these compounds provide advantages over the use of the nucleoside analogue alone. It also makes it possible to incorporate them into the lamellar structure of liposomes, either alone or combined with similar molecules. In the form of liposomes, these antiviral agents are preferentially taken up by macrophages and monocytes, cells which have been found to harbor the target HIV virus. Additional site specificity may be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins. Effective nucleoside analogues are dideoxynucleosides, azidothymine (AZT), and acyclovir; lipid groups may be glycolipids, sphingolipids, phospholipids or fatty acids. The compounds persist, after intracellular hydrolysis, as phosphorylated or non-phosphorylated antiviral nucleosides. The compounds are effective in improving the efficacy of antiviral nucleoside analogues by prolonging the antiviral activity after the administration of the drug has ended, and in preventing retroviral replication in HIV infections which have become resistant to therapy with conventional forms of the antiretroviral agents.
PROBLEM TO BE SOLVED: To obtain a new complex having antifungal activities, and capable of being an active ingredient of a more strong and excellent antifungal agent. SOLUTION: This complex is an imidazole compound coordinated metal complex of the formula, MLm Xn [M is a metal atom; L is an imidazole compound ligand with antifungal activities; X is an anionic ligand; (m) and (n) are each independently an integer of 1-3, and 2&lt;=(m)+(n)&lt;=5], preferably a complex of formula I (X&#39; is a halide ion; R and R&#39; are each independently a lower alkyl or a lower alkenyl), and for example, the complex of formula II is cited. The compound is obtained by reacting compounds of formulas III and IV (preferably oxyconazole, ketoconazole, etc.), with a metal halide. The complex has a low toxicity, and can be administered to mammal such as the human safely. The complex is administered as an antifungal agent as it is or by preparing into a pharmaceutical preparation, because of being stable and having safe and strong antifungal activities.
Methods and apparatus for providing and using a portable electronic data storage and information retrieval system for healthcare and/or other types of applications are described. Each portable storage device (PSD) (e.g., smart card) for a group, e.g., household, allows the storage and retrieval of household level information in addition to individual household member data/information. Data/information is stored corresponding to different applications. The PSD is accessed by a service provider&#39;s computer system. Access to the data/information is secured via authentication and/or various encryption techniques. Various service providers or types of service providers have access to different portions of the information stored on the portable storage device based upon pre-arranged agreements and/or service needs. Access is controlled through security information and/or security modules which are used to limit access. Service providers can update network based information databases and/or update the information on the PSD, e.g., to indicate a particular service or treatment.
PURPOSE:To obtain an anticancer agent containing phospholipid or diacylglycerol as an active ingredient. CONSTITUTION:A phospholipid (e.g. phosphatidyl choline, phosphatidyl serine or phosphatidyl inositol) or diacylglycerol (e.g. dilinoleoylglycelol or 1-oleoyl-2- acetylglycerol) is incorporated as an active ingredient to provide the aimed anticancer agent. Liposome of the phospholipid is at first prepared by subjecting the phospholipid dried in a nitrogen gas stream to supersonic treatment in a phosphoric acid buffer containing no Ca&lt;2+&gt; and Mg&lt;2+&gt; in order to prepare the aimed agent. The preparation is sufficiently carried out at a treating temperature of 25 deg.C and treating time of about 60sec. The anticancer agent brings innovative progress to remedy for cancer of the lung which has been short of good treating method so far, but the agent is not limited to only cancer of the lung.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a desiccant which shows high safety when a person takes in the desiccant by accident, with regard to the desiccant usd for a medicine, foodstuff, etc. and also shows excellent moisture absorption characteristics.  &lt;P&gt;SOLUTION: The problem can be solved by adding an arginine acidic amino acid salt to the desiccant. That is, the applicable arginine acidic amino acid salt is of a such type that can be obtained in nature, or with the help of a microbe and from a processed product of the microbe or by a chemical synthesis, etc. Besides, the commercial grade product of the amino acid salt can be used. In addition, for the acidic amino acid salt, a glutamate is preferably used. Besides, the desiccant can be used by bringing it into contact directly with the medicine or foodstuff or mixing it with a base for formulation.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To prepare a cosmetic having improved dispersibility and miscibility of an inorganic pigment in an oily raw material, and improved applicability, safety, stability and feeling, etc., to the skin, by compounding an inorganic pigment surface-treated with a specific N-mono-long-chain acyl basic amino acid. CONSTITUTION:The surface of an inorganic pigment is treated with an N-mono- long-chain-acyl basic amino acid containing one 8-22C aliphatic acyl group in the molecule, e.g. N&lt;alpha&gt;- or N&lt;epsilon&gt;-long-chain-acyl lysine, N&lt;alpha&gt;- or N&lt;delta&gt;-long-chain-acyl ornithine, N&lt;alpha&gt;- or N&lt;gamma&gt;-long-chain-acyl-alpha,gamma-diaminobutyric acid, etc. The treated inorganic pigment is compounded to a cosmetic to improve the above characteristics of the cosmetic. A cosmetic having uniform quality, free from stickiness, giving smooth feeling to the skin, spreadable easily on the skin, having durable cosmetic effect, forming little peroxides, and having various other advantages can be prepared by this process. The amount of the amino acid is preferably 0.05-5wt% based on the inorganic pigment.
Subject of the present invention is an isolated human nucleic acid molecule encoding polypeptides containing a homeobox domain of sixty amino acids having the amino acid sequence of SEQ ID NO: 1 and having regulating activity on human growth. Three novel genes residing within the about 500kb short stature critical region on the X and Y chromosome were identified. At least one of these genes is responsible for the short stature phenotype. The cDNA corresponding to this gene may be used in diagnostic tools, and to further characterize the molecular basis for the short stature-phenotype. In addition, the identification of the gene product of the gene provides new means and methods for the development of superior therapies for short stature. &lt;IMAGE&gt;
A medical implant for injecting into the vascular system of animals comprises a device less than 500um in size carrying signal processing for providing an output in response to an input signal. The input may be acoustic, electromagnetic, temperature pH value, or chemical. The output may be acoustic, electromagnetic, or chemical. Large numbers e.g. 10&#34; of the implant devices may be mixed into a saline solution and injected into a blood vessel where they are carried round the vascular system. Alternatively the devices may be mixed with a gas and inhaled. The amount of circulation depends on the device size. For the larger device e.g. above 7um to around 250um, circulation will be short lived. Smaller sized e.g. &lt; 3um devices will circulate for a considerbale time. Antibodies may be coated onto the devices to cause them to adhere to target areas e.g. tumours. In one device a chemical is released when illuminated externally by an acoustic beam. In another device a chemical Is released when the pH of surrounding blood changes to a given level. Power to operate the device may be by an Integral battery.
FIELD: medicine.SUBSTANCE: invention relates to medicine, more specifically to transplantology, and can be used in the preparation of a recipient for liver transplantation. Such method for slowing the progression of liver cirrhosis in recipients on a waiting list for liver transplantation involves the production of mononuclear cells (MNCs) from autologous biological material. As an autologous biological material, the bone marrow of the recipient is used, which is obtained by the method of trepan aspiration in an amount of 200–300 ml bilaterally from the posterior tuberosity of the ilium. MNCs are isolated from the obtained material, their viability and the number of hematopoietic stem cells in them are estimated. Then, the speed of the recipient&#39;s portal blood flow is determined, uniform contrast of all segmental branches of the portal vein is provided, as well as no blood flow through the collaterals. Next, an automated intraportal injection of the MNCs with an injector is performed. After that, at least once every two months, the MELD integral indicators and the Child-Turcotte-Pugh score are used to assess the quality of life of the recipient, the results of ultrasonic elastometry of the liver are evaluated every 3 months, as well as a morphological and immunohistochemical study of liver biopsies before and after the introduction of cells. If the obtained data are preserved in the dynamics at the initial level or improve, the slow progression of cirrhosis of the liver is present.EFFECT: use of this method allows to slow the progression of liver cirrhosis in recipients by introducing MNCs at a rate equal to the velocity of the recipient&#39;s portal blood flow, ensuring a decrease in the loss of MNCs through collaterals.1 cl, 1 ex, 3 tbl, 8 dwg
PROBLEM TO BE SOLVED: To obtain a hair tonic capable of improving the function of the hair of the head and scalp, preventing the alopecia and having hair tonic and growth effects. SOLUTION: This hair tonic contains extracted solutions obtained by immersing Sesamum indicum L., Swertia japonica Makino and Hibiscus syriacus L. in an alcoholic extracted solution of Impatiens balsamica L. as a solvent as active ingredients. The amounts of the ingredients are 2-4 pts.wt. extract solution of the Impatiens balsamica L., 2-4 pts.wt. aqueous solution containing ethyl alcohol at &gt;=20 deg., 3-5pts. wt. extract solution of the Sesamum indicum L., 1-2 pts.wt. extracted solution of the Swertia japonica Makino, 1-2 pts.wt. extracted solution of the Hibiscus syriacus L, and, as necessary, further 1-2 pts.wt. extracted solution of a seaweed is mixed therewith. The resultant mixture is then allowed to stand for 7-10 days and aged.  Furthermore, a coloring matter, a perfume, a germicide, a preservative, etc., are suitably blended and prepared as a hair tonic, a hair lotion, a hair conditioner, a shampoo, a rinse, etc., for use.
1324619 Polyvalent poultry vaccine SHIONOGI &amp; CO Ltd 23 Dec 1971 [29 Dec 1970] 59288/72 Divided out of 1324618 Heading ASB A killed poultry vaccine comprises killed infections bronchitis virus and killed Newcastle disease virus. The infections bronchitis virus may be of the Geaudette, Massachusetts or Connecticut type. The Newcastle disease virus may be of the Sato or Miyadera type. The vaccine may also include killed hemophilus gallinarum which has been cultivated on a natural nutrient medium and inactivated before harvesting. The vaccine may also include an antiseptic, e.g. thimerosal, #-propiolactone, tyosin, salicylic acid, crystal violet, benzoic acid, polymyxin, gramicidin or benzethionium chloride, aluminium hydroxide gel, aluminium phosphate gel, calcium phosphate gel, or alum. The vaccine may be administered intracutaneously, subcutaneously or intramuscularly.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical diagnostic device capable of securing the security of medical data without damaging the operability of the medical image diagnostic device.  &lt;P&gt;SOLUTION: In the case of authenticating fingerprints by using a fingerprint sensor 71b, by combining the fingerprint sensor 71b with a reset switch 71a for resetting testee body information, the reset of the testee body information and authentication can be performed by one operation. That is, in the case of executing an examination to a new testee body, since the reset switch 71a for resetting the testee body information is surely pressed, the fingerprint is authenticated surely by the fingerprint sensor 71b. Thus, the need of placing a finger on the fingerprint sensor 71b and authenticating it separately other than the operation of pressing the switch for resetting the testee body information is eliminated. While securing the operability in such a manner, the security is secured as well.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI